Organon & Co (OGN)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 6,403,000 | 6,263,000 | 6,174,000 | 6,304,000 | 8,096,000 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $6,403,000K ÷ $—K
= —
The information provided for Organon & Co's Receivables turnover ratio for the years ending December 31, 2020 to December 31, 2024 is not available. This ratio is used to evaluate how efficiently a company is managing its credit sales and collecting on outstanding receivables within a specific period. The absence of data for this ratio makes it difficult to assess the company's effectiveness in converting credit sales into cash. It is vital to monitor this ratio over time to understand the company's ability to collect its accounts receivable promptly and efficiently.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Organon & Co
OGN
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—